ArticleCureus2026
Effect of Electrical Stimulation of the Quadriceps Muscles in the Management of Haemophilic Knee Arthropathy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hemarthrosis is the most common disabling manifestation of haemophilia, and recurrent knee bleeding leads to haemophilic arthropathy with pain, muscle wasting, and functional limitation. Evidence on the added benefit of electrical stimulation (ES) in conjunction with therapeutic exercise for haemophilic knee arthropathy is limited, particularly in low-resource settings. So, this study was planned to evaluate the effect of quadriceps ES as an adjunct to isometric quadriceps exercise (IQE) on pain, muscle strength, muscle bulk, bleeding events, and functional status in patients with haemophilic knee arthropathy. Methods This quasi-experimental study was conducted at Dhaka Medical College Hospital from October 2021 to September 2022. Patients aged 12-41 years with mild-moderate haemophilia and mild-moderate haemophilic knee arthropathy were assigned purposively to Group A (ES + IQE; n = 25) or Group B (IQE alone; n = 26). IQE was prescribed twice daily for six months. Group A additionally received quadriceps ES (50 Hz, 15 minutes) twice weekly for the first three months. Outcomes (pain by visual analogue scale (VAS), muscle power by Medical Research Council (MRC) scale, muscle bulk by mid-thigh circumference, bleeding events, and functional outcome by Bangla validated Western Ontario and McMaster Osteoarthritis (WOMAC)) were assessed monthly for six months. Results Baseline characteristics were comparable between the groups. From the third follow-up onward, Group A showed significantly lower pain scores compared with Group B (VAS: 4.08 ± 0.64 vs 4.87 ± 0.86; p-value: 0.002), which remained significant at the sixth follow-up (4.00 ± 0.76 vs 4.69 ± 0.92; p-value: 0.006). Muscle strength improved significantly in Group A, with 52.0% achieving MRC grade 5 compared with 15.4% in Group B at the third follow-up (p-value: 0.006). Muscle bulk was also significantly greater in Group A from the third follow-up (34.89 ± 4.35 cm vs 31.42 ± 3.48 cm; p-value: 0.011). Functional outcomes improved significantly in the intervention group, with lower WOMAC total scores from the second follow-up (38.84 ± 5.15 vs 44.62 ± 4.67; p-value: 0.008) and highly significant differences by the sixth follow-up (p-value: <0.001). Bleeding events were infrequent and did not differ significantly between the groups during the follow-up period. Conclusions Quadriceps ES combined with IQE provides superior pain relief, strength gains, muscle bulk, and functional improvement, without increasing bleeding risk, in mild-to-moderate haemophilic knee arthropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.